Crossmark

Modifying Rap1-signalling by targeting Pde6δ is neuroprotective in models of Alzheimer’s disease

Crossref DOI link: https://doi.org/10.1186/s13024-018-0283-3

Published Online: 2018-09-26

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dumbacher, Michael

Van Dooren, Tom

Princen, Katrien

De Witte, Koen

Farinelli, Mélissa

Lievens, Sam

Tavernier, Jan

Dehaen, Wim

Wera, Stefaan

Winderickx, Joris

Allasia, Sara

Kilonda, Amuri

Spieser, Stéphane

Marchand, Arnaud

Chaltin, Patrick

Hoogenraad, Casper C.

Griffioen, Gerard
Funding

Funding for this research was provided by:

FP7 People: Marie-Curie Actions (289581)

Agentschap Innoveren en Ondernemen

European Research Council (340941)
License Information

Text and Data Mining valid from 2018-09-26
More Information

Article History

Received: 4 December 2017

Accepted: 13 September 2018

First Online: 26 September 2018

Ethics approval and consent to participate

: All experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (NRC, 2011) and the European Communities Council Directive of September 22nd, 2010.

: Not applicable.

: MD, TVD, KP, KDW and GG are employed by reMYND. TVD, KP, KDW, GG, SW and JW own reMYND warrants and/or stocks. MF employed by E-Phy-Science and owns stocks. SL is employed by Orionis Biosciences. SW employed by ViroVet and owns stocks.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.